A new experimental drug for spinal muscular atrophy from Roche subsidiary Genentech is showing promise, according to new data published Wednesday.

The new data shows that the drug, risdiplam, could help children with the debilitating illness sit up and move more easily. It’s an incremental new data set, but one that hints that the drug, if approved, could ultimately compete with Biogen’s pricey drug for the same condition, Spinraza. And the CEO of PTC Therapeutics, from which Genentech licensed the drug, is already hinting that the drug’s backers could file a new drug application with the FDA by the end of 2019.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy